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Abstract
Background: We investigated the association between exposure to trichloroethylene (TCE) and
mutations in the von Hippel-Lindau (VHL) gene and the subsequent risk for renal cell carcinoma
(RCC).
Methods: Cases were recruited from a case-control study previously carried out in France that
suggested an association between exposures to high levels of TCE and increased risk of RCC. From
87 cases of RCC recruited for the epidemiological study, 69 were included in the present study.
All samples were evaluated by a pathologist in order to identify the histological subtype and then
be able to focus on clear cell RCC. The majority of the tumour samples were fixed either in
formalin or Bouin's solutions. The majority of the tumours were of the clear cell RCC subtype (48
including 2 cystic RCC). Mutation screening of the 3 VHL  coding exons was carried out. A
descriptive analysis was performed to compare exposed and non exposed cases of clear cell RCC
in terms of prevalence of mutations in both groups.
Results: In the 48 cases of RCC, four VHL mutations were detected: within exon 1 (c.332G>A,
p.Ser111Asn), at the exon 2 splice site (c.463+1G>C and c.463+2T>C) and within exon 3
(c.506T>C, p.Leu169Pro).
No difference was observed regarding the frequency of mutations in exposed versus unexposed
groups: among the clear cell RCC, 25 had been exposed to TCE and 23 had no history of
occupational exposure to TCE. Two patients with a mutation were identified in each group.
Conclusion: This study does not confirm the association between the number and type of VHL
gene mutations and exposure to TCE previously described.
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Background
Renal cell carcinoma (RCC), the most frequent malig-
nancy in the adult kidney, is usually sporadic [1]. The phe-
notype is extremely heterogeneous and several
classifications of renal epithelial tumours have been pro-
posed [2,3]. Main histological subtypes of renal epithelial
tumours include clear-cell RCC (75%), papillary RCC
(10–15%), chromophobe RCC (5%) and oncocytomas
(5%). Inactivation of the VHL tumour suppressor gene is
thought to result both in development of tumors in the
von Hippel-Lindau (VHL) disease (MIM #19330) and in
sporadic clear-cell RCC [4]. Germline mutations of VHL
gene are responsible for VHL disease, a rare dominantly
inherited cancer syndrome predisposing to a number of
highly vascularized tumors including multiple clear-cell
RCC whereas somatic mutation or methylation of VHL
gene is a frequent event in sporadic clear-cell RCC [4,5].
Trichloroethylene (TCE) is a solvent used in numerous
industries, as degreaser in the metal manufacturing indus-
try, solvent for oils and resins, or the production of rubber
and as a chemical intermediate in the production of refrig-
erants. A number of epidemiological studies have investi-
gated the association between exposure to
trichloroethylene and renal cell cancer but the results have
been inconsistent [6]. A cohort study conducted in a card-
board factory and a case-control study conducted in the
same area in Germany found significantly elevated risk for
renal cell cancer and trichloroethylene occupational expo-
sure [7,8]. For subjects in that case control study, a specific
pattern of mutations in the VHL gene has been reported in
RCC cases with former prolonged and high-level expo-
sures to trichloroethylene [9]. However, another study
carried out in Germany to evaluate the phenotype and the
genotype of renal tumours in occupationally TCE-exposed
patients revealed no unique phenotype, genotype or
mutation pattern in the VHL gene of renal tumours after
TCE exposure [10].
In France, the results of a case-control study performed in
a geographic area with a high frequency and intensity of
exposure suggested an association between exposures to
high levels of TCE and increased risk of RCC [6,11,12].
Thus it seemed to be of interest to further expand this
case-control study with a molecular analysis to confirm or
not the specific pattern of VHL mutations associated with
trichloroethylene exposure reported in the German study.
The objective of the study was to test the hypothesis of an
association between exposure to trichloroethylene and
VHL mutations and the subsequent risk for RCC.
Materials and Methods
Tumour samples
Cases were recruited from the case-control study previ-
ously carried out in the Arve Valley [6,11,12]. For the spe-
cific analysis on VHL mutations, patients were informed
of the objectives of this study and a new written consent
was requested. With the patients' consent (or that of their
next-of-kin) we collected tumour tissues from the various
pathologists. General information and exposure data were
obtained from the epidemiological study.
A total of 87 cases of renal cell cancer had been recruited
for the epidemiological study. From these, 69 accepted to
be included in the present study. Formalin and Bouin's
fixed paraffin-embedded tissue samples from 64 patients
with renal tumours were cut and transferred onto glass
slides. Furthermore, 5 frozen tumours were included in
this series. After H&E staining, all samples were evaluated
by a specialized pathologist in order to identify the histo-
logical subtype and then focus on clear cell RCC. Forty-
one samples were paraffin-embedded tissue fixed in
Bouin's and 23 in formalin solution. The majority of the
tumours were of the clear cell RCC subtype: 46 were solid
clear cell RCC and 2 were cystic clear cell RCC.
DNA extraction
Genomic DNA was extracted from tumour samples with
ten 7 µm sections of paraffin blocks loaded on standard
slides focusing on the 48 clear cell RCC previously identi-
fied. The blade was cleaned after each block to prevent
cross contamination between the samples. Each slide was
scraped with a scalpel in order to recover only tumour tis-
sue, by comparison with an H&E staining of the same sec-
tion. The QIAamp DNA Mini Kit (Qiagen, Courtaboeuf,
France) was used, with 2 slight modifications. First, sam-
ples were digested during 18 hours at 56°C with protein-
ase K to obtain complete digestion. Second, paraffin was
not removed by xylene extraction: we used instead the fact
that the paraffin wax melts during the later 56°C incuba-
tion. Microtubes were centrifuged at full speed for 10 min
at 4°C to remove all paraffin. Finally, the total amount of
DNA was measured by Nanodrop technology (Labtech
France, Paris, France).
Mutation analysis
Mutation screening of the 3 VHL coding exons and exon-
intron junctions was performed thanks to two groups of
primers available on request. The first group of primers
was designed to amplify exon 1 in two overlapping frag-
ments, exon 2 and exon 3 in one fragment each, the four
fragments comprising approximately 300 bp. The second
group was designed to amplify exon 1 in 4 fragments,
exons 2 and 3 in two fragments each, corresponding to
fragments of 100–150 bp. Since the yield after PCR ampli-
fication was not always satisfactory, nested PCR were per-
formed with 25 and then 35 cycles. Briefly, tumour DNA
aliquots were used in a 10 µL final reaction volume com-
prising 1X Q solution and buffer with 15 mM of MgCl2,
0.8 mM of dNTP mix, 0.3 µM of each forward and reverse
primers and 0.5 U of HotStarTaq® DNA Polymerase (Qia-Journal of Occupational Medicine and Toxicology 2007, 2:13 http://www.occup-med.com/content/2/1/13
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gen). A negative control was introduced in all PCR exper-
iments. PCR products were analyzed on standard 1.5%
agarose gels stained with ethidium bromide (0.5µg/mL)
before purification with ExoSAP-IT (Amersham Bio-
sciences, Saclay, France). Sequencing reactions were per-
formed using Big Dye Terminator (Applied Biosystems,
Courtaboeuf, France), purified through Sephadex G-50
(Amersham Biosciences) and run on an ABI 3730 Genetic
Analyzer (Applied Biosystems). Sequence files were
aligned and analyzed by Sequencher v4.2.2 (Gene Codes
Corporation, Ann Arbor, USA) software. All sequence
alterations were verified independently by reamplifying
the corresponding fragment and repeating the sequencing
procedure using both forward and reverse primers.
Statistical analysis
The mutation data were analyzed with the UMD-VHL
software [13] to compare them with previous somatic
mutations [25].
A descriptive analysis was performed to compare exposed
and non exposed cases of clear cell RCC in terms of prev-
alence of mutations in both groups.
The statistical analysis was performed using the SAS sys-
tem 9.1.3.
Legal agreement
Before starting the study an agreement was obtained from
the CCPPRB Lyon A (consultative committee for persons
protection in biomedical research). Then an approval was
obtained from the French Ministry of Research (Comité
consultatif pour le traitement de l'information en matière de
recherche dans le domaine de la santé) and the French data
protection authority (Commission Nationale de l'Informa-
tique et des Libertés) was informed about the study.
Results
Mutation analysis
Mutation screening was performed on the 48 confirmed
cases of clear cell RCC, comprising 26 Bouin's fixed
tumours, 17 were formalin fixed and 5 frozen tumours.
For all of the frozen samples the VHL gene was success-
fully PCR amplified and sequenced, compared to 71% (12
of 17) of the formalin-fixed samples, and 38% (10 of 26)
of the Bouin's fixed tissues. Thus, the VHL  gene was
entirely sequenced (ie 100% of the coding sequence ana-
lysed) for a total of 26 tumours (54%). A VHL mutation
was detected in one of the frozen samples at the exon 2
splice site (c.463+1G>C). Furthermore, three VHL muta-
tions were detected in the fixed tumours: one mutation
within exon 1 (c.332G>A, p.Ser111Asn), one at the exon
2 splice site (c.463+2T>C), and the last one within exon 3
(c.506T>C, p.Leu169Pro), see Figure 1. These three cases
were fixed in formalin solution. No mutations were found
in the samples fixed in Bouin's solution. Regarding the
codon 81, 75% of the samples (31 fixed and 5 frozen
tumours respectively) were successfully sequenced for the
corresponding PCR fragment in exon 1 and no mutation
at this particular codon was observed.
Exposure to TCE
The mean of sequencing percentage was 86.1 (+/-19.5)
among exposed cases and 80.3 (+/-27.3) among non-
exposed cases, this difference is not significant (p = 0.40).
The sequencing rate reached 100% for 15 cases (60.0%) of
the exposed group versus 11 (48%) cases of the non
exposed group (p = 0.30).
The codon 81 was seen for 20 (80%) of the exposed cases
and 16 (70%) of the non exposed cases (p = 0.40).
No difference was observed regarding the frequency of
mutations in exposed versus unexposed groups (Table 1).
Indeed, among the clear cell RCC, 25 had been exposed to
TCE and 23 had no history of occupational exposure to
TCE. Two patients with a mutation were identified in each
group. In the exposed group, 9 (36%) patients had been
exposed to a low cumulative dose, 4 (16%) to a medium
cumulative dose and 12 (48%) to a high cumulative dose
of TCE.
If we consider only renal clear cell tumours for which the
VHL gene was entirely sequenced, among 15 patients who
had been exposed to TCE, 6 (40%) had been exposed to a
low cumulative dose, 3 (20%) to a medium cumulative
dose and 6 (40%) to a high cumulative dose. Two of the
mutations identified occurred in TCE exposed cases but
only one of these had been highly exposed. Description of
exposures in patients for which a mutation was identified
is presented in Table 2.
Discussion
It has been postulated that sporadic and familial renal cell
carcinomas have a common carcinogenic pathway and
that at least one gene should be altered in both forms. This
has been confirmed with the cloning of the VHL gene and
the identification of germline and somatic mutations of
this gene in VHL patients and sporadic RCC. Today, more
than 400 germline mutations have been reported in VHL
patients and about 300 somatic mutations in sporadic
RCC [13]. The collection of a large number of mutations
is necessary to identify key residues in the biological func-
tion of the protein, for molecular epidemiology and to
establish correlations between the localization of the
mutation and specific phenotypes. In a previous study,
Beroud et al. [14-16] have shown that the somatic and
germline mutational events are different with only 22% of
missense mutations in sporadic RCC vs 63% in familial
cases (p < 0.001). They also showed that the distributionJournal of Occupational Medicine and Toxicology 2007, 2:13 http://www.occup-med.com/content/2/1/13
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Sequence chromatograms of the 4 mutations identified in the VHL gene in this study Figure 1
Sequence chromatograms of the 4 mutations identified in the VHL gene in this study. R and T are DNA from a commercially 
available reference and tumour tissue tested respectively. Panels A, B and C correspond to 3 different renal clear cell tumours 
fixed in formalin solution, whereas panel D corresponds to one of the frozen tumours.
Table 1: Mutation frequency according to exposure to TCE
No mutation Mutation Fisher bilateral exact test (p)
Sequencing percentage: any rate
N = 48
Non exposed to TCE
N = 23
21 (91%) 2 (9%) 1.00
Exposed to TCE
N = 25
23 (92%) 2 (8%)
Sequencing percentage 100%
N = 26
Non exposed to TCE
N = 11
9 (82%) 2 (18%) 1.00
Exposed to TCE
N = 15
13 (87%) 2 (13%)Journal of Occupational Medicine and Toxicology 2007, 2:13 http://www.occup-med.com/content/2/1/13
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of missense mutations is different in the two groups with
68% of missense mutations corresponding to transver-
sion in somatic mutations vs 35% in germline mutations
(p < 0.001). Since it is thought that transversions impli-
cate an extrinsic factor, these data support the hypothesis
of the involvement of environmental factors in the aetiol-
ogy of sporadic RCC [17-19]. Brüning et al. studied the
RCC incidence in individuals with former prolonged and
high-level exposures to TCE [20]. They found a specific
pattern of VHL somatic mutations with a high frequency
in exon 2. In 1999, Brauch et al. completed these data and
showed multiple intragenic mutations within the same
tumour (42% of cases), a very high proportion of C>T
transitions (70%) and a hot spot of mutations at codon
81 (p.Pro81Ser) [9]. Altogether these data suggest a role of
TCE or its metabolites in these mutational events. To
explore this further, we have compared the distribution of
somatic VHL mutations in RCC from patients exposed to
TCE (from Brüning [20] and Brauch [9]) with the RCC
somatic mutations in the UMD-VHL database [13] that
collects all published mutations of the VHL gene. The pur-
pose of this analysis was to compare specific pattern of
VHL mutations thought to be associated with TCE expo-
sure with a wider collection of VHL gene information.
This comparison confirms that the specific pattern of
mutations identified by Brüning [20] and Brauch [9] is
different from the pattern in the large UMD-VHL database
of somatic VHL mutations in RCC tumours. In fact, this
somatic mutation pattern suspected to be associated with
TCE exposures is much closer to the germline mutation
profile with an excess of missense mutations. In addition,
50% (16 out of 32) of these missense mutations are C>T
transitions with 13 involving codon 81. As these transi-
tions do not involve a CpG dinucleotide, we can suspect
that they result from the exposure to a toxic substance or
any other carcinogen.
In addition the distribution of somatic mutations reveals
that the codon 81 has been involved in only one tumour
from studies other than those of Brüning et al [20] and
Brauch et al. [9]. Overall mutations at this position could
be specifically associated to exposure to trichloroethylene.
It is however surprising, considering the intensive use of
TCE all over the world, that this specific mutation has not
been reported in other case series. In our series, no muta-
tion was detected at this particular codon, indicating that,
as observed by Schraml et al [10], we have not confirmed
the results of Brüning et al. [20] and Brauch et al. [9].
The present study was performed in blinded test fashion
regarding TCE exposure data. The series comprised 48
cases of confirmed clear cell RCC. All of these cases had
been included in a case control study previously pub-
lished. 26 of the tumours were Bouin's solution-fixed, 17
were formalin-fixed and 5 were frozen tumours. As
reported in the literature, molecular analysis based on
archival tissues is possible however often difficult [21].
Actually, formic acid contained in formalin solution, fixa-
tion time and period of storage of the tissue blocks often
affect the quality of DNA. Furthermore, picric acid con-
tained in Bouin's solution is known to degrade nucleic
acids, thus a low yield of PCR amplification of DNA could
be obtained. Here 26 tumours (21 fixed and 5 frozen
tumours, ie 54%) were successfully analyzed regarding
the VHL gene. However, codon 81 was seen for 80% of the
cases of clear cell RCC who had been exposed to TCE.
Three mutations were detected in the fixed tumours,
within exon 1 (c.332G>A, p.Ser111Asn), exon 2 splice site
(c.463+2T>C) and exon 3 (c.506T>C, p.Leu169Pro).
These three cases were fixed in formalin solution. No
mutation was found in the samples fixed in Bouin's solu-
tion. Regarding the 5 frozen tumours, one mutation was
detected at the exon 2 splice site (c.463+1G>C). The 4
mutations detected in the present study have been
described in previous VHL  studies: they are reported
Table 2: Description of patient with a VHL gene mutation
Patient A Patient B Patient C Patient D
Type of mutation c.463+2 T>C c.332 G>A c.506 T>C c.463+1 G>C
Age at diagnosis 52 years 58 years 63 years 42 years
Sex man women man man
Exposure to TCE yes no yes no
Conditions of exposure 2 years to 15 ppm in screw 
cutting industry during
highly exposed (cumulative 
dose 830 ppm.years with 
peaks)
Other occupational 
exposures identified
cutting oils asbestos cutting oils in screw cutting 
industry
other chlorinated solvents, 
cutting oils, lead, ionizing 
radiations, asbestos and 
welding fumes
none of the exposures 
studied
Tobacco smoking 12 pack-years never 20 pack-years never
Body Mass Index < 25 > 30 < 25 between 25 and 30Journal of Occupational Medicine and Toxicology 2007, 2:13 http://www.occup-med.com/content/2/1/13
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between 1 and 4 times either at the germline or somatic
level in the VHL Mutation Database [25].
Interestingly, it is reported in the literature that a VHL
somatic mutation is detected in approximately half of
sporadic clear cell RCC [14,22,23]. Thus, among the 48
clear cell RCC tumours analyzed in the present study, at
least 20 samples would be expected to carry a VHL muta-
tion compared to 4 mutations detected here. However,
these 4 mutations were detected in a series of 26 clear cell
RCC for which the VHL gene was entirely sequenced, cor-
responding to 15%. As a number of fixed samples could
not be successfully PCR amplified because of DNA degra-
dation, we cannot exclude that some of these samples
carry a VHL mutation. However, it was recently suggested
a new cause of occupational cancer where there was a
molecular analysis of VHL without mutation detected in
this gene, suggesting that other genes may be implicated
in RCC and in particular linked to chemical exposure [24].
The VHL gene can be inactivated somatically, besides loss
of heterozygosity, either by mutation or promoter hyper-
methylation. The quality of the DNA extracted from fixed
tumours did not allow us to analyze the methylation sta-
tus of the VHL promoter. Thus, we cannot exclude that
some tumours may involve hypermethylation.
In the present study, 25 (52%) of the clear cell RCC cases
concerned patients who had been exposed to TCE, 12
(48%) of them had been exposed to high cumulative
dose. Despite this high rate of exposure to TCE and the
rate of complete sequencing (100% for 26 of 48 cases of
RCC), only two of the patients for which a mutation was
identified had been exposed to TCE and only one of them
had been highly exposed the cumulative exposure reach-
ing 830 ppm× years. However this patient had also been
exposed to many other occupational risks including expo-
sures to carcinogens (asbestos and ionizing radiation).
Three of the patient for which a mutation was identified
had been exposed to cutting oils.
When considering cases of renal clear cell cancers with a
rate of VHL sequencing reaching 100%, the rate of muta-
tions was not statistically different among patients who
had been exposed to TCE and among those who had not,
respectively 13% and 18%.
In summary we conclude that this study has not con-
firmed the association between the number and type of
VHL  gene mutations and exposure to TCE previously
described. However, due to methodological limitations,
these results do not allow to totally rule out this specific
association.
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